期刊
EXPERIMENTAL AND MOLECULAR MEDICINE
卷 50, 期 -, 页码 -出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/s12276-018-0115-0
关键词
-
资金
- Ministry of Health & Welfare, Republic of Korea [HI13C2148]
- Ministry of Science, ICT & Future Planning [2015K1A4A3047851]
- National Research Foundation of Korea [2017R1E1A1A01074913, 2012R1A5A2047939]
- Ewha Womans University
Cancer immunotherapy is a promising way to eliminate tumor cells by using the patient's own immune system. Selecting the appropriate animal models to develop or validate preclinical immunotherapeutic trials is now an important aspect of many cancer research programs. Here we discuss the advantages and limitations of using genetically engineered immunodeficient mouse models, patient-derived xenografts (PDXs), and humanized mouse models for developing and testing immunotherapeutic strategies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据